These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19345039)

  • 1. Morbidity associated with Pseudomonas aeruginosa bloodstream infections.
    Scheetz MH; Hoffman M; Bolon MK; Schulert G; Estrellado W; Baraboutis IG; Sriram P; Dinh M; Owens LK; Hauser AR
    Diagn Microbiol Infect Dis; 2009 Jul; 64(3):311-9. PubMed ID: 19345039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study.
    Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Fattah MA; Haquin J; MacGowan A; Grier S; Chazan B; Yanovskay A; Ami RB; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Maurer S; Rodriguez-Bano J; Morales I; Oliver A; de Gopegui ER; Cano A; Machuca I; Gozalo-Marguello M; Martinez-Martinez L; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
    Int J Antimicrob Agents; 2020 Feb; 55(2):105847. PubMed ID: 31770625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.
    Bowers DR; Liew YX; Lye DC; Kwa AL; Hsu LY; Tam VH
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1270-4. PubMed ID: 23263001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudomonas aeruginosa bloodstream infection at a tertiary referral hospital for children.
    Dame JA; Beylis N; Nuttall J; Eley B
    BMC Infect Dis; 2020 Oct; 20(1):729. PubMed ID: 33028225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia.
    Su TY; Ye JJ; Hsu PC; Wu HF; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2015 Apr; 48(2):175-82. PubMed ID: 24064286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.
    Micek ST; Lloyd AE; Ritchie DJ; Reichley RM; Fraser VJ; Kollef MH
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1306-11. PubMed ID: 15793102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia.
    Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM
    J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome.
    Jeong SJ; Yoon SS; Bae IK; Jeong SH; Kim JM; Lee K
    Diagn Microbiol Infect Dis; 2014 Oct; 80(2):130-5. PubMed ID: 25112900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of severity of illness scoring systems for patients with nosocomial bloodstream infection due to Pseudomonas aeruginosa.
    Marra AR; Bearman GM; Wenzel RP; Edmond MB
    BMC Infect Dis; 2006 Aug; 6():132. PubMed ID: 16916466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study.
    Pilmis B; Alby-Laurent F; Fasola ML; Seegers V; Guery R; Guet-Revillet H; Postaire M; Toubiana J; Bille E; Lortholary O; Zahar JR
    Eur J Pediatr; 2020 Aug; 179(8):1247-1254. PubMed ID: 32080759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.
    Lodise TP; Patel N; Kwa A; Graves J; Furuno JP; Graffunder E; Lomaestro B; McGregor JC
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3510-5. PubMed ID: 17646415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model to predict mortality following Pseudomonas aeruginosa bacteremia.
    Hirsch EB; Cottreau JM; Chang KT; Caeiro JP; Johnson ML; Tam VH
    Diagn Microbiol Infect Dis; 2012 Jan; 72(1):97-102. PubMed ID: 22056006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia.
    Cheong HS; Kang CI; Wi YM; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
    Eur J Clin Microbiol Infect Dis; 2008 Dec; 27(12):1219-25. PubMed ID: 18575908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections.
    Peña C; Cabot G; Gómez-Zorrilla S; Zamorano L; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez-López F; Tubau F; Martínez-Martínez L; Oliver A;
    Clin Infect Dis; 2015 Feb; 60(4):539-48. PubMed ID: 25378459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for the failure of treatment of
    Yoshida S; Suzuki K; Suzuki A; Okada H; Niwa T; Kobayashi R; Murakami N; Ogura S; Itoh Y
    Pharmazie; 2017 Jul; 72(7):428-432. PubMed ID: 29441942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality.
    Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Macas A; Sakalauskas R
    Medicina (Kaunas); 2010; 46(7):490-5. PubMed ID: 20966623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
    Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F
    Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.